Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 22Neoplasms 17Neoplasm Metastasis 16Breast Neoplasms 16Triple Negative Breast Neoplasms 10Colorectal Neoplasms 9Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Melanoma 5Carcinoma, Pancreatic Ductal 5Adenocarcinoma 5Small Cell Lung Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Rectal Neoplasms 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Hodgkin Disease 3Fallopian Tube Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Ductal Adenocarcinoma 2Nasopharyngeal Carcinoma 2

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT06769425 2025-06-24

HS-10502

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
157 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡